Janux Therapeutics (JANX) Receivables - Net (2020 - 2024)
Janux Therapeutics (JANX) has disclosed Receivables - Net for 5 consecutive years, with $7.5 million as the latest value for Q2 2024.
- On a quarterly basis, Receivables - Net changed N/A to $7.5 million in Q2 2024 year-over-year; TTM through Jun 2024 was $7.5 million, a N/A change, with the full-year FY2020 number at $8.0 million, changed N/A from a year prior.
- Receivables - Net was $7.5 million for Q2 2024 at Janux Therapeutics, up from $519000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $8.0 million in Q4 2020 to a low of $400000.0 in Q2 2021.
- A 5-year average of $3.0 million and a median of $659500.0 in 2023 define the central range for Receivables - Net.
- Biggest YoY gain for Receivables - Net was 35.12% in 2024; the steepest drop was 35.12% in 2024.
- Janux Therapeutics' Receivables - Net stood at $8.0 million in 2020, then tumbled by 95.0% to $400000.0 in 2021, then rose by 25.0% to $500000.0 in 2022, then soared by 60.0% to $800000.0 in 2023, then soared by 837.5% to $7.5 million in 2024.
- Per Business Quant, the three most recent readings for JANX's Receivables - Net are $7.5 million (Q2 2024), $519000.0 (Q1 2024), and $800000.0 (Q1 2023).